INTRACEPT: Prospective, Randomized, Multi-center Study Intraosseous Basivertebral Nerve Ablation for Treatment of CLBP

NCT ID: NCT03246061

Last Updated: 2024-04-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-24

Study Completion Date

2024-03-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, open-label, 1:1 randomized controlled trial of Basivertebral nerve (BVN) Ablation arm vs Standard Care Control for the treatment of vertebrogenic chronic low back pain (CLBP). Participants in the the BVN Ablation arm will receive radiofrequency ablation of the BVN using the Intracept procedure for treatment of up to 4 vertebral bodies (L3 to S1). Participants in the Standard Care Control arm will continue on non-surgical standard care and will be offered optional crossover after 12 months of follow-up with follow-up of 6 months post crossover treatment.

The study had a pre-specified Interim Analysis with stopping rules for superiority when approximately 60% of the randomized participants have completed their 3-month primary endpoint study visit. An independent Data Safety Management Board (DSMB) reviewed the interim analysis results and recommended stopping enrollments for superiority and offering early crossover to the control arm participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants in the BVN Ablation arm will be followed for 24 months following treatment. BVN Ablation arm participants will be approached to participate in a sub study of 3 additional years of follow-up at their 24 month visit (total of 5 years of follow-up).

Control arm subjects who were originally to be offered optional crossover treatment after the 12 month follow-up visit were offered crossover per the DSMB recommendation at a mean of 176.5 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Low Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

BVN Ablation vs Standard Care Control
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BVN Ablation

BVN ablation with continued standard care

Group Type ACTIVE_COMPARATOR

Intracept System

Intervention Type DEVICE

BVN ablation using radiofrequency energy

Standard Care Control

Continue with non-surgical standard care

Group Type ACTIVE_COMPARATOR

Standard Care

Intervention Type OTHER

Non-surgical standard care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intracept System

BVN ablation using radiofrequency energy

Intervention Type DEVICE

Standard Care

Non-surgical standard care

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Skeletally mature subjects at least 25 years of age
* Chronic lower back pain for at least 6 months
* Failure to respond to at least 6 months of non-operative conservative management

Exclusion Criteria

* Radicular pain
* Current or history of spinal infection
* Modic changes at vertebral bodies other than L3 to S1
* Contraindication to MRI
* Pregnant, lactating or plan to become pregnant in next year
* Has life expectancy of less than 2 years
* Compensated injuries or ongoing litigation regarding back pain/injury, or financial incentive to remain impaired
Minimum Eligible Age

25 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Relievant Medsystems, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Steven R Garfin, MD

Role: PRINCIPAL_INVESTIGATOR

Independent

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Clinical Therapeutics

Birmingham, Alabama, United States

Site Status

Barrow Brain and Spine

Phoenix, Arizona, United States

Site Status

Keck Medicine of USC

Los Angeles, California, United States

Site Status

Stanford Orthopaedic Surgery

Redwood City, California, United States

Site Status

Denver Back Specialists

Greenwood Village, Colorado, United States

Site Status

Emory University School of Medicine

Atlanta, Georgia, United States

Site Status

Drug Studies America

Marietta, Georgia, United States

Site Status

Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

St Luke's Hospital

Kansas City, Missouri, United States

Site Status

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Bassett Medical Center

Cooperstown, New York, United States

Site Status

University of Rochester

Rochester, New York, United States

Site Status

OrthoCarolina

Charlotte, North Carolina, United States

Site Status

Clinical Investigations

Edmond, Oklahoma, United States

Site Status

Pacific Sports and Spine

Eugene, Oregon, United States

Site Status

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Temple University

Philadelphia, Pennsylvania, United States

Site Status

Precision Spine Center

Tyler, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

http://intraceptstudy.com

INTRACEPT Study Website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIP 0006

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Central Pain Study for ABX-1431
NCT03138421 COMPLETED PHASE1